Integrated UPLC-MS/MS Metabolomics Reveals Novel Metabolic Markers for Type I Endometrial Carcinogenesis in Clinical Samples
This study utilized integrated UPLC-MS/MS metabolomics and transcriptomics on paired clinical samples to identify 436 differential metabolites and key pathways, such as ferroptosis and ABC transporters, that characterize Type I endometrial carcinogenesis and offer novel biomarkers for diagnosis and treatment.